The University of Southampton
University of Southampton Institutional Repository

Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases

Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases
Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
1389-4501
1430-1438
Shuttleworth, Stephen J.
303af312-bed4-49b5-8d79-e80d7b6d96da
Bailey, Sarah G.
3907c846-1c65-490a-81f1-653fea9ff7f0
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db
Shuttleworth, Stephen J.
303af312-bed4-49b5-8d79-e80d7b6d96da
Bailey, Sarah G.
3907c846-1c65-490a-81f1-653fea9ff7f0
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db

Shuttleworth, Stephen J., Bailey, Sarah G. and Townsend, Paul A. (2010) Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Current Drug Targets, 11 (11), 1430-1438. (doi:10.2174/1389210205839724501). (PMID:20583972)

Record type: Article

Abstract

The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.

This record has no associated files available for download.

More information

Published date: November 2010

Identifiers

Local EPrints ID: 161299
URI: http://eprints.soton.ac.uk/id/eprint/161299
ISSN: 1389-4501
PURE UUID: 9f38c63a-14e5-41d3-83ee-a934d8252731

Catalogue record

Date deposited: 27 Jul 2010 14:32
Last modified: 14 Mar 2024 01:59

Export record

Altmetrics

Contributors

Author: Stephen J. Shuttleworth
Author: Sarah G. Bailey
Author: Paul A. Townsend

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×